Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Gynecologic 1Breast 1

Conditions

Pancreatic Neoplasms 358Carcinoma, Non-Small-Cell Lung 178Neoplasms 109Breast Neoplasms 97Lung Neoplasms 81Urinary Bladder Neoplasms 79Neoplasm Metastasis 74Ovarian Neoplasms 53Cholangiocarcinoma 39Sarcoma 38Lymphoma 38Biliary Tract Neoplasms 35Gallbladder Neoplasms 34Hodgkin Disease 30Lymphoma, Non-Hodgkin 27Adenocarcinoma 27Lymphoma, Large B-Cell, Diffuse 25Colorectal Neoplasms 24Bile Duct Neoplasms 23Triple Negative Breast Neoplasms 22Recurrence 22Fallopian Tube Neoplasms 22Unspecified Adult Solid Tumor, Protocol Specific 21Carcinoma, Transitional Cell 21Carcinoma, Ovarian Epithelial 21Urethral Neoplasms 20Carcinoma 17Adenocarcinoma of Lung 15Head and Neck Neoplasms 14Carcinoma, Renal Cell 14

Interventions

Imatinib Mesylate 41Sunitinib 17nilotinib 12regorafenib 10ripretinib 6avapritinib 6Leucovorin 3Ipilimumab 3Gemcitabine 3Dasatinib 3CTLA-4 Antigen 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2Paclitaxel 2Oxaliplatin 2Midazolam 2Irinotecan 2Fluorouracil 2Floxuridine 2Erlotinib Hydrochloride 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2Biopsy, Fine-Needle 2Bevacizumab 2vatalanib 1umbralisib 1trametinib 1tinostamustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Stromal Tumors × Gemcitabine × Clear all
NCT02632448 2025-05-02

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma Inc.

Phase 1/2 Completed
229 enrolled
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Triple Negative Breast Neoplasms

NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT00359333 2013-10-30

STS

National Health Research Institutes, Taiwan

Phase 2 Completed
58 enrolled
GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡